Brief: Geneuro H1 Net Loss Widens To EUR 6.9 Mln

Geneuro SA

02/10/2023 06:42

Oct 2 (Reuters) - Geneuro SA  GNRO.PA :
    * H1 CASH POSITION OF EUR 7.4 MILLION
    * ONGOING PHASE II CLINICAL TRIAL EVALUATING TEMELIMAB IN
PATIENTS
WITH "LONG-COVID"
    * H1 NET LOSS AT EUR 6.9 MILLION
    * H1 OPERATING LOSS EUR 7.1 MILLION VERSUS LOSS EUR 4.9
MILLION
YEAR AGO
    * FINANCIAL VISIBILITY INTO Q3 2024: THE COMPANY’S CASH
PROVIDES
FINANCIAL VISIBILITY INTO Q3 2024, AFTER THE EXPECTED COMPLETION
OF THE LONG-COVID CLINICAL TRIA
    * €25 MILLION CREDIT LINE WITH THE EUROPEAN INVESTMENT BANK
BACKED
BY INVESTEU, TO SUPPORT CLINICAL DEVELOPMENTS AGAINST LONG-COVID

Source text for Eikon:  ID:nBw15cTZba 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))